Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : British Government Secures COVID-19 Antivirals from Merck & Co., Pfizer

10/20/2021 | 11:20pm EST


ę MT Newswires 2021
All news about MERCK & CO., INC.
10:06aNew Analysis Shows Merck COVID-19 Pill Molnupiravir Less Effective Than Previously Repo..
MT
08:51aMerck & Co. Says Molnupiravir Cuts Risk of Severe COVID-19 Based on Trial Data
MT
07:41aMerck, Ridgeback Biotherapeutics' Molnupiravir Drug Reduced Risk of Severe COVID-19 Bas..
MT
06:46aMerck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Mo..
BU
05:56aUK To Test Merck & Co.'s COVID-19 Pill In National Study
MT
03:46aPfizer, Merck Reportedly Agree to License Production of Respective Experimental COVID-1..
MT
02:07aPfizer, Merck & Co. Set to Allow Vietnamese Companies to Produce COVID-19 Pill
MT
11/24Truist Securities Adjusts Merck's Price Target to $95 From $92, Reiterates Buy Rating
MT
11/24Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
BU
11/24Gilead Sciences, Merck Pause Phase 2 HIV Trial
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 600 M - -
Net income 2021 13 638 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 16,3x
Yield 2021 3,28%
Capitalization 200 B 200 B -
EV / Sales 2021 4,54x
EV / Sales 2022 3,78x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 79,16 $
Average target price 96,70 $
Spread / Average Target 22,2%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-3.23%207 835
JOHNSON & JOHNSON1.82%421 847
ROCHE HOLDING AG17.17%334 769
PFIZER, INC.38.25%285 639
NOVO NORDISK A/S68.76%247 704
ELI LILLY AND COMPANY55.18%237 527